Get the latest news, insights, and market updates on MEDP (Medpace Holdings, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
How Medpace’s Q3 2025 Surge and Buybacks Strategy Could Impact Medpace Holdings (MEDP) Investors
Recently, Giverny Capital Asset Management highlighted Medpace Holdings as a key portfolio position after the contract research organization reported a 23.7% year-over-year revenue increase in its third quarter of 2025. The company’s strong organic growth, accelerating demand outlook, and history of share buybacks have drawn attention to how its business model converts clinical trial momentum into earnings power. Next, we’ll explore how Medpace’s strong organic revenue growth and improving... Dec 14, 2025 - $MEDP
2 Profitable Stocks to Keep an Eye On and 1 We Find Risky
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity". Dec 12, 2025 - $MEDP
What Makes Medpace Holdings (MEDP) an Investment Choice?
Giverny Capital Asset Management, LLC, an investment management company, recently published its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The portfolio generated good results in the third quarter and returned 6.78% compared to 8.12% for the S&P 500. YTD, the fund returned 12.57% compared to 14.83% for the index. […] Dec 9, 2025 - $MEDP
1 Volatile Stock to Target This Week and 2 We Turn Down
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy. Dec 8, 2025 - $MEDP
Is It Too Late to Consider Medpace After Its Strong 2024 Share Price Surge?
If you are wondering whether Medpace Holdings at around $548 a share is still worth considering after its huge run, or if you are late to the party, you are in the right place. Despite a sharp pullback of around 7.5% over the last week and 7.0% over the last month, the stock is still up 63.7% year to date and 56.4% over the past year, with 3 and 5 year returns of 166.4% and 291.5% respectively. Recent headlines have focused on Medpace winning new clinical research contracts, expanding... Dec 7, 2025 - $MEDP
Medpace (MEDP): Assessing Valuation After Revenue Growth, Buybacks and AI-Driven Clinical Trial Expansion
Medpace Holdings (MEDP) is back in the spotlight after Q2 results showed revenue climbing on efficient backlog conversion, while sizable share repurchases and ongoing AI investments in patient recruitment reinforced management’s confidence and the company’s competitive position. See our latest analysis for Medpace Holdings. Despite a choppy last month, with an 8.5% 30 day share price return decline, Medpace’s 63.7% year to date share price return and 56.4% one year total shareholder return... Dec 6, 2025 - $MEDP
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple